1. Home
  2. CGC vs AKBA Comparison

CGC vs AKBA Comparison

Compare CGC & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Canopy Growth Corporation

CGC

Canopy Growth Corporation

HOLD

Current Price

$1.03

Market Cap

404.3M

Sector

Health Care

ML Signal

HOLD

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$0.96

Market Cap

375.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CGC
AKBA
Founded
N/A
2007
Country
Canada
United States
Employees
N/A
N/A
Industry
Pharmaceuticals and Biotechnology
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
404.3M
375.0M
IPO Year
2023
2014

Fundamental Metrics

Financial Performance
Metric
CGC
AKBA
Price
$1.03
$0.96
Analyst Decision
Hold
Strong Buy
Analyst Count
1
3
Target Price
N/A
$4.67
AVG Volume (30 Days)
6.8M
5.5M
Earning Date
05-29-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
36.75
93.94
EPS
N/A
N/A
Revenue
$12,759,000.00
N/A
Revenue This Year
$8.27
N/A
Revenue Next Year
$15.68
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.84
$0.88
52 Week High
$2.38
$4.08

Technical Indicators

Market Signals
Indicator
CGC
AKBA
Relative Strength Index (RSI) 44.05 34.17
Support Level $0.99 $0.88
Resistance Level $1.23 $1.56
Average True Range (ATR) 0.05 0.07
MACD -0.00 -0.00
Stochastic Oscillator 40.22 23.90

Price Performance

Historical Comparison
CGC
AKBA

About CGC Canopy Growth Corporation

Canopy Growth Corp, cultivates and sells medicinal and recreational cannabis and hemp through a portfolio of brands that include Doja, LivRelief, Ace Valley, Deep Space, and others. The Company is engaged in reportable segments namely: Canada cannabis, International markets cannabis, Storz & Bickel, and This Works. The company generates maximum revenue from Canadian cannabis.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

Share on Social Networks: